anayamalik, Author at European Medical Journal - Page 110 of 120

The Teen Brain’s Secret Weapon Against Pain?

Resilience in adolescents with juvenile fibromyalgia (JFM) may significantly alleviate emotional symptoms, providing fresh insights for clinicians treating this complex chronic pain condition.

Clinical Implications of Metformin on COPD

Metformin, commonly prescribed for diabetes, may reduce the risks of exacerbation and hospitalization in patients with chronic obstructive pulmonary disease (COPD).

FDA Lifts Hold on COVID-Flu Combo Vaccine Trial

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a late-stage trial of a combined COVID-19 and influenza vaccine candidate, allowing the study to resume following an investigation into a reported adverse event.

Emergency Department Costs: $207M and 2,143 Young Lives

A national study recently highlighted the potential life-saving impact of enhancing emergency departments’ (ED) pediatric readiness across the United States.

Annual DXA Screening “Essential” After Lung Transplant

A newly published study recommends annual DXA screenings for patients in the first 2 years after lung transplants to monitor bone mineral density (BMD) changes.

Rwanda Nears End of Marburg Outbreak

Rwanda has begun the 42-day countdown to officially declare an end to the Marburg virus outbreak, having discharged its last patient on November 8, 2024.

How Does Asthma Alter Children’s Memory Development?

Children with asthma, particularly those with an early onset, may experience slower memory development and face challenges in cognitive functions.

New Algorithm Enhances Precision in Long COVID Cohorts

Researchers have developed a precision phenotyping algorithm that significantly advances the identification of long COVID, or post-acute sequelae of COVID-19 (PASC), in patient records.

Newborn Genome Screening Shows 99.6% Success Rate

In a landmark study conducted across six New York City hospitals, researchers have found that genomic sequencing can significantly enhance newborn screening by detecting additional actionable conditions beyond the current standard newborn screening (NBS) program.

New Genetic Insight on Leukemia Treatment Resistance

A genetic variant, the BIM deletion polymorphism (BDP), has been identified by researchers to significantly enhance leukemia stem and progenitor cells’ survival, making them resistant to common targeted therapies.